Adaptimmune Therapeutics plc (ADAP) Reaches $14.06 52-Week High; Cullen Capital Management Has Decreased By $4.78 Million Its Intel Corp. (INTC) Position

May 9, 2018 - By Peter Erickson

Intel Corporation (NASDAQ:INTC) Logo

Cullen Capital Management Llc decreased Intel Corp. (INTC) stake by 6.23% reported in 2017Q4 SEC filing. Cullen Capital Management Llc sold 103,825 shares as Intel Corp. (INTC)’s stock rose 9.61%. The Cullen Capital Management Llc holds 1.56M shares with $72.19M value, down from 1.67 million last quarter. Intel Corp. now has $249.36 billion valuation. The stock decreased 0.22% or $0.12 during the last trading session, reaching $53.51. About 7.22 million shares traded. Intel Corporation (NASDAQ:INTC) has risen 44.65% since May 9, 2017 and is uptrending. It has outperformed by 33.10% the S&P500.

The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) hit a new 52-week high and has $14.76 target or 5.00% above today’s $14.06 share price. The 6 months bullish chart indicates low risk for the $1.32 billion company. The 1-year high was reported on May, 9 by Barchart.com. If the $14.76 price target is reached, the company will be worth $66.20 million more. The stock increased 9.50% or $1.22 during the last trading session, reaching $14.06. About 408,027 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has risen 144.20% since May 9, 2017 and is uptrending. It has outperformed by 132.65% the S&P500.

Since January 22, 2018, it had 0 insider buys, and 18 selling transactions for $6.85 million activity. Shenoy Navin also sold $436,410 worth of Intel Corporation (NASDAQ:INTC) shares. Krzanich Brian M had sold 5,873 shares worth $267,663 on Tuesday, January 23. RENDUCHINTALA VENKATA S M had sold 1,502 shares worth $66,959. Shares for $31,943 were sold by McBride Kevin Thomas on Wednesday, February 21.

Investors sentiment decreased to 1.02 in 2017 Q4. Its down 0.01, from 1.03 in 2017Q3. It fall, as 60 investors sold INTC shares while 703 reduced holdings. 177 funds opened positions while 601 raised stakes. 3.06 billion shares or 0.43% more from 3.05 billion shares in 2017Q3 were reported. 113,816 are owned by Brown Advisory Secs Ltd Liability Company. Jpmorgan Chase And invested in 0.17% or 17.36 million shares. Fairfield Bush holds 14,550 shares. Suntrust Banks Inc has invested 0.65% in Intel Corporation (NASDAQ:INTC). Longer Invs holds 53,810 shares or 2.08% of its portfolio. Glynn Capital Management Ltd Liability Com invested in 0.5% or 50,000 shares. Callan Cap Ltd Liability reported 0.08% stake. Patten & Patten Tn owns 1.79% invested in Intel Corporation (NASDAQ:INTC) for 387,648 shares. Pzena Investment Ltd Llc owns 7,019 shares. Osterweis Capital Management Inc invested in 663,669 shares. Commerce Comml Bank holds 0.73% or 1.22 million shares. Northpointe Cap Limited holds 0.47% of its portfolio in Intel Corporation (NASDAQ:INTC) for 90,773 shares. Foundry Prtn Ltd Liability Corporation holds 9,721 shares or 0.02% of its portfolio. Sunbelt Securities Inc holds 0.25% of its portfolio in Intel Corporation (NASDAQ:INTC) for 5,489 shares. Boyd Watterson Asset Management Ltd Liability Company Oh reported 63,611 shares or 1.42% of all its holdings.

Cullen Capital Management Llc increased Vermilion Energy Inc. (NYSE:VET) stake by 39,427 shares to 142,827 valued at $5.20 million in 2017Q4. It also upped Japan Tobacco Inc. (JAPAF) stake by 38,300 shares and now owns 175,460 shares. Honda Motor Co. Ltd. was raised too.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Seekingalpha.com which released: “Qualcomm’s Exit Is Intel’s Gain” on May 09, 2018, also Bizjournals.com with their article: “Intel Capital teams with NBA to find and fund future sports tech” published on May 08, 2018, Fool.com published: “Intel Corp.’s Contract Chip Manufacturing Business Will Fail” on May 07, 2018. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Nasdaq.com and their article: “4 Top Stock Trades for Wednesday Morning” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Intel: The 15-Plus Year Breakout – Part 2” with publication date: April 28, 2018.

Among 55 analysts covering Intel Corporation (NASDAQ:INTC), 36 have Buy rating, 3 Sell and 16 Hold. Therefore 65% are positive. Intel Corporation had 262 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained it with “Buy” rating and $4300 target in Wednesday, July 12 report. The stock of Intel Corporation (NASDAQ:INTC) earned “Buy” rating by Jefferies on Thursday, July 21. The firm has “Buy” rating given on Thursday, July 21 by Mizuho. The rating was maintained by Rosenblatt with “Sell” on Friday, April 27. Jefferies maintained it with “Sell” rating and $3000 target in Friday, July 28 report. On Thursday, September 1 the stock rating was initiated by Roth Capital with “Buy”. As per Tuesday, April 17, the company rating was maintained by Susquehanna. Jefferies maintained Intel Corporation (NASDAQ:INTC) rating on Wednesday, July 5. Jefferies has “Hold” rating and $3800 target. The rating was downgraded by Stifel Nicolaus to “Hold” on Thursday, April 5. The stock has “Buy” rating by FBR Capital on Thursday, January 25.

More important recent Adaptimmune Therapeutics plc (NASDAQ:ADAP) news were published by: Globenewswire.com which released: “Adaptimmune Reports First Quarter 2018 Financial Results and Business Update” on May 09, 2018, also Globenewswire.com published article titled: “Adaptimmune Announces Changes to Board of Directors”, Nasdaq.com published: “Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018” on April 18, 2018. More interesting news about Adaptimmune Therapeutics plc (NASDAQ:ADAP) was released by: Prnewswire.com and their article: “Technical Perspectives on Biotech Stocks — Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and …” with publication date: April 19, 2018.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $1.32 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Among 7 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Adaptimmune Therapeutics PLC has $20.0 highest and $10.0 lowest target. $15’s average target is 6.69% above currents $14.06 stock price. Adaptimmune Therapeutics PLC had 8 analyst reports since February 25, 2016 according to SRatingsIntel. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Buy” rating by SunTrust on Saturday, November 11. The stock has “Buy” rating by Cowen & Co on Friday, March 16. Leerink Swann initiated the shares of ADAP in report on Friday, March 16 with “Buy” rating. The stock has “Buy” rating by Cowen & Co on Tuesday, June 6. The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) earned “Underperform” rating by Bank of America on Monday, October 24. The firm has “Buy” rating given on Thursday, February 25 by Citigroup.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>